SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update;Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización

Revista Espanola de Cirugia Ortopedica y Traumatologia

Volumn 59, Issue 6, 2015, Pages 373-393

  Etxebarria Foronda, I ^a,b   Caeiro Rey, J R ^a,c   Larrainzar Garijo, R ^a,d   Vaquero Cervino, E ^a,e   Roca Ruiz, L ^a,f   Mesa Ramos, M ^a,g   Merino Perez J ^a,h   Carpintero Benitez, P ^a,i   Fernandez Cebrian A ^a,j   Gil Garay, E ^a,k  

^a GEIOS SECOT   (Spain)

^b Hospital Alto Deba   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^e Servicio de Cirugía Ortopédica y Traumatología   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g Unidad de Gestión Clínica del Aparato Locomotor   (Spain)

^h HOSPITAL DE CRUCES   (Spain)

ⁱ Universidad de Cordoba   (Spain)

^j Nephrology Department   (Spain)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; VITAMIN; VITAMIN D;

ALGORITHM; CLINICAL DECISION MAKING; COMPLICATION; DECISION SUPPORT SYSTEM; FEMALE; FRACTURE FIXATION; HEALTH STATUS INDICATOR; HIP FRACTURES; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PHOTON ABSORPTIOMETRY; PRACTICE GUIDELINE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SPAIN; SPINAL FRACTURES; X-RAY COMPUTED TOMOGRAPHY;

ABSORPTIOMETRY, PHOTON; ALGORITHMS; BONE DENSITY CONSERVATION AGENTS; CLINICAL DECISION-MAKING; COMBINED MODALITY THERAPY; DECISION SUPPORT TECHNIQUES; FEMALE; FRACTURE FIXATION; HEALTH STATUS INDICATORS; HIP FRACTURES; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; RISK FACTORS; SPAIN; SPINAL FRACTURES; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D; VITAMINS;

EID: 84938149667     PISSN: 18884415     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.recot.2015.05.007     Document Type: Short Survey

References (141)

1. Ivegard M., Svedbom A., Hernlund E., Compston J., Cooper C., Stenmark J., et al. Epidemiology and economic burden of osteoporosis in Spain. Arch Osteoporos 2013, 8:195-218.
2. Auais M., Morin S., Nadeau L., Finch L., May N. Changes in frailty-related characteristics of the hip fracture population and their implications for healthcare services: Evidence from Quebec, Canada. Osteoporos Int 2013, 24:2713-2724.
3. Azagra R., López-Expósito F., Martín-Sánchez J.C., Aquyé A., Moreno N., Cooper C., et al. Changing trends in the epidemiology of hip fractures in Spain. Osteoporos Int 2014, 25:1267-1274.
4. Etxebarria-Foronda I., Mar J., Arrospide A., Esnal-Baza E. Trends in the incidence of hip fractures in women in the Basque Country. Arch Osteoporos 2010, 5:131-137.
5. Cooper C., Campion G., Melton L.J. Hip fractures in the elderly: A world wide projection. Osteoporosis Int. 1992, 2:285-289.
6. Bass E., French D.D., Bradham D.D., Rubenstein L.Z. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol. 2007, 17:514-519.
7. Instituto de Información Sanitaria. Estadísticas comentadas: La Atención a la Fractura de Cadera en los hospitales del SNS [Publicación en Internet]. Madrid: Ministerio de Sanidad y Política Social; 2010 [consultado 18 Dic 2913]. Disponible en: http://www.msps.es/estadEstudios/estadisticas/cmbdhome.htm.
8. Manzarbeitia J. Las fracturas de cadera suponen un coste de 25.000 millones de euros al año en la UE. Rev Esp Econ Salud 2005, 4:216-217.
9. Alvarez-Nebreda M.L., Jiménez A.B., Rodríguez P., Serra J.A. Epidemiology of hip fracture in the elderly in Spain. Bone 2008, 42:278-285.
10. Serra J.A., Garrido G., Vidán M., Marañón E., Brañas F., Ortiz J. Epidemiología de la fractura de cadera en ancianos en España. An Med Interna 2002, 19:389-395.
11. Vega-Rodríguez N., Limiñana Cañal J.M., Arbelo-Rodríguez A., Medina-Henríquez J.A., Cabrera-Domínguez D., Blázquez-Gómez C., et al. Epidemiología de la fractura de cadera en Gran Canaria durante el quinquenio 2007-2011. Rev Osteoporos Metab Miner 2013, 1:30-35.
12. Hernández J.L., Olmos J.M., Alonso M.A., González-Fernández C.R., Martínez J., Pajarón M., et al. Trend in hip fracture epidemiology over a 14-year period in a Spanish population. Osteoporos Int 2006, 17:464-470.
13. Olmos J.M., Martínez J., García J., Matorras P., Moreno J.J., González-Macías J. Incidencia de la fractura de cadera en Cantabria. Med Clin (Barc) 1992, 99:729-731.
14. Altadill A., Gómez C., Virgós M.J., Díaz B., Cannata J.B. Epidemiología de la fractura de cadera en Asturias. Med Clin (Barc) 1995, 105:281-286.
15. Herrera A., Martínez A.A., Fernández L., Gil E., Moreno A. Epidemiology of osteoporotic hip fracture in Spain. International Orthopaedics 2006, 30:11-14.
16. Oleksik A., Lips P., Dawson A., Minshall M.E., Shen W., Cooper C., et al. Health-related quality of life in postmenopausal women with low BMD with or withouth prevalent vertebral fractures. J Bone Miner Res 2000, 15:1384-1392.
17. Jalava J.A., Sarina S., Pylkkanen L., Mawer B., Kanis J.A., Selby P., et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 2003, 18:1254-1260.
18. Bell J.E., Leung B.C., Spratt K.F., Koval K.J., Weinstein J.D., Goodman D.C., et al. Trends and variation in incidence, surgical treatment and repeat surgery of proximal humeral fractures in the elderly. J Bone Joint Surg Am 2011, 93:121-131.
19. Calvo E., Morcillo D., Foruria A.M., Redondo-Santamaría E., Osorio-Picorne F., Caeiro J.R. Non-displaced proximal humeral fractures: High incidence among outpatient-treated osteoporotic fractures and severe impact on upper extremity function and patient subjective health perception. J Shoulder Elbow Surg 2011, 20:795-801.
20. Amorosa L.F., Vitale M.A., Brown S., Kaufmann R.A. A functional outcomes survey of elderly patients who sustained distal radius fractures. Hand 2011, 6:260-267.
21. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17:1726-1733.
22. González-Montalvo J.L., Alarcón T., Hormigo-Sánchez A.I. Why do hip fracture patients die?. Med Clin (Barc) 2011, 137:355-360.
23. Klotzbuecher C.M., Ross P.D., Lansman P.B., Abbott T.A., Berger M. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Miner Res 2000, 15:721-739.
24. Caeiro J.R., Bartra A., Mesa M., Etxebarria I., Montejo J., Carpintero P., et al. Uso de recursos sanitarios y coste de la fractura de cadera en España: Estudio observacional, prospectivo PROA. Rev Osteoporos Metab Miner 2014, 3:13-44.
25. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001, 285:785-795.
26. Gosch M., Kammerlander C., Roth T., Doshi H.K., Gasser R.W., Blauth M. Surgeons save bones: An algorithm for orthopedic surgeons managing secondary fracture prevention. Arch Orthop Trauma Surg 2013, 133:1101-1108.
27. Herrera Rodríguez A., Cáceres Palau E., Caeiro Rey J.R., Canales Cortés V., Curto Gamallo J.M., Fernández Baillo N., et al. Recomendaciones de manejo clínico del paciente mayor de 50 años con fractura osteoporótica. Rev Esp Enferm Metab Oseas 2003, 12:125-128.
28. Mesa-Ramos M., Carpintero R., Maquieira C., Zabala M. Escalas de valoración de riesgos de osteoporosis y fractura osteoporótica 2009, Multimedica Proyectos, Madrid.
29. González-Macías J., Marín F., Vila J., Díez-Pérez A., Abizanda M., Álvarez R., et al. Prevalencia de factores de riesgo de osteoporosis y fracturas osteoporóticas en una serie de 5195 mujeres mayores de 65 años. Med Clin (Barc) 2004, 123:85-89.
30. Tebé C., del Río L.M., Casas L., Estrada M.D., Kotzeva A., di Gregorio S., et al. Factores de riesgo de fracturas por fragilidad en una cohorte de mujeres españolas. Gac Sanit 2011, 25:507-512.
31. Azagra R., Roca G., Encabo G., Prieto D., Aguyé A., Zwart M., et al. Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: Validation of the WHO FRAX™ tool in Spain. BMC Musculoskelet Disord 2011, 12:30.
32. Sanfélix-Genovés J., Sanfélix-Gimeno G., Peiró S., Hurtado I., Fluixa C., Fuertes A., et al. Prevalence of osteoporotic fracture risk factors and osteoporotic treatments in the Valencia región, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporos Int 2013, 24:1045-1055.
33. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1108-1112.
34. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
35. Azagra R., Roca G., Encabo G., Aguyé A., Zwart M., Güel S., et al. FRAX™ tool, the WHO algorithm to predict osteoporotic fractures: The first analysis of its discriminative and predictive ability in the Spain FRIDEX cohort. BMC Musculoskelet Disord 2012, 13:204.
36. Tebé Cordomí C., del Río L.M., di Gregorio S., Casas L., Estrada M.D., Kotzeva A., et al. Validation of the FRAX predictive model for major osteoporotic fracture in a historical cohort of Spanish women. J Clin Densitom 2013, 16:231-237.
37. González-Macías J., Marín F., Vila J., Díez-Pérez A. Probability of fractures predicted by FRAX and observed incidence in the Spanish ECOSAP Study cohort. Bone 2012, 50:373-377.
38. Jódar Gimeno E. Conclusiones consensuadas del I Foro Multidisciplinar en el manejo del paciente con alto riesgo de fractura osteoporótica. Rev Osteoporos Metab Miner 2010, 2:79-86.
39. National Osteoporosis Foundation. Newly Revised 2013 Clinician's Guide to Prevention and Treatment of Osteoporosis 2010, 14-16. National Osteoporosis Foundation, Washington, DC.
40. Jódar E. Evaluación y diagnóstico de la osteoporosis. Osteoporosis. Guía de fácil manejo 2003, 15-36. Profármaco, Barcelona. J. Blanch, E. Jódar, M. Sosa (Eds.).
41. Stein E., Shane E. Secondary osteoporosis. Endoc Metab Clin North Am 2003, 32:115-134.
42. Orwoll E., Ettinger M., Weiss S., Miller P., Kendler D., Graham J., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604-610.
43. Melton L.J., Achenbach S.J., O'Fallon W.M., Khosla S. Secondary osteoporosis and the risk of distal forearm fractures in men and women. Bone. 2002, 31:119-125.
44. Caeiro J.R., Vaquero E., Mesa M. Prevención de las fracturas osteoporóticas mediante métodos farmacológicos: Punto de vista del cirujano ortopédico y traumatólogo. Revista Argentina de Osteología 2006, 5:17-37.
45. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000, 11(Suppl 6):S2-S17.
46. Singh M., Nagrath A., Maini P.S. Changes in trabecular patterns of the upper of the femur as an index of osteoporosis. J Bone Joint Surg Am 1970, 54:457-467.
47. Sosa M. La fractura vertebral: una entidad en busca de definición. Med Clin (Barc) 2000, 115:661-662.
48. Genant H.K., Wu C.Y., van Kujik C., Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8:1137-1148.
49. Majumdar S.R., Kim N., Colman I., Chahal A.M., Raymond G., Jen H., et al. Incidental vertebral fractures discovered with chest radiography in the emergency department: Prevalence, recognition and osteoporosis management in a cohort of elderly patients. Arch Intern Med 2005, 165:905-909.
50. Blake G.M., Fogelman I. An update on dual-energy X-ray absorptiometry. Semin Nucl Med 2010, 40:62-73.
51. Mueller D., Gandjour A. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women. Value Health 2009, 12:1106-1117.
52. National Institute for Health and Clinical Excellence (NICE). Osteoporosis: assessing the risk of fragility fracture. NICE clinical guideline 146; 2012 [consultado 15 Jul 2014]. Disponible en: http://www.nice.org.uk/guidance/cg146/resources/guidance-osteoporosis-assessing-the-risk-of-fragility-fracture-pdf.
53. Osteoporosis: Diagnosis, Treatment and Fracture Prevention 2011, 3-4. British Columbia Medical Association, Ministry of Health.
54. Ensrud K.E., Thompson D.E., Cauley J.A., Nevitt M.C., Kado D.M., Hochberg M.C., et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 2000, 48:241-249.
55. Longo U.G., Loppini M., Denaro L., Maffulli N., denaro V. Conservative management of patients with an osteoporotic vertebral fractures. J Bone Joint Surg Br 2012, 94:152-157.
56. Pfeifer M., Begerow B., Minne H.W. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: A randomized trial. Am J Phys Med Rehabil 2004, 83:177-186.
57. Lamy O., Uebelhart B., Aubry-Rozier B. Risks and benefits of percutaneous vertebroplasty or kyphoplasty in the management of osteoporotic vertebral fractures. Osteoporos Int 2014, 25:807-819.
58. Nikolau V.S., Efstathopoulos N., Kontakis G., Kanakaris N.K., Giannoudis P.V. The influence of osteoporosis in femoral fracture healing time. Injury 2009, 40:663-668.
59. Potter J.F. The older orthopaedic patient: General considerations. Clin Orthop Relat Res 2004, 425:44-49.
60. The Royal Australian College of General Practitioners. Clinical guideline for prevention and treatment of osteoporosis in postmenopausal women and older men 2010, The RACGP, South Melbourne.
61. British Columbia Ministry of Health and British Columbia Medical Association. BC Guidelines. Osteoporosis: Diagnosis, Treatment and Fracture Prevention. Effective Date: May 1, 2011. Revised: October 1, 2012 [consultado 15 Jul 2014]. Disponible en: http://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines.
62. Kanis J.A., McCloskey E.V., Johansson H., Cooper C., Rizzoli R., Reginster J.Y. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013, 24:23-57.
63. Bolland M.J., Avenell A., Baron J.A., Grey A., MacLennan G.S., Gamble G.D., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis. BMJ 2010, 341:c3691.
64. Abrahamsen B., Sahota O. Do calcium plus vitaminD supplements increase cardiovascular risk?. BMJ 2011, 342:d2080.
65. Pérez Edo L., Alonso Ruiz A., Roig Vilaseca D., García Vadillo A., Guañabens Gay N., Peris P., et al. Actualización 2011 del Consenso de la Sociedad Española de Reumatología de Osteoporosis. Reumatol Clin. 2011, 7:357-379.
66. Guía de Práctica Clínica Osteoporosis. Grupo de Estudio e Investigación en Osteoporosis y Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS) 2010, 89-98. Multimédica Proyectos, Madrid.
67. Duaso E., Casas A., Formiga F., Lázaro del Nogal M., Salvà A., Marcellán T., et al. Unidades de prevención de caídas y de fracturas osteoporóticas. Propuesta del Grupo de Osteoporosis, Caídas y Fracturas de la Sociedad Española de Geriatría y Gerontología. Rev Esp Geriatr Gerontol 2011, 46:268-274.
68. Mesa-Ramos M., Caeiro-Rey J.R., Etxebarría-Foronda I., Carpintero-Benítez P. Aspectos de interés para el cirujano ortopédico y traumatólogo sobre la vitamina D. Rev Esp Cir Ortop Traumatol 2012, 56:164-173.
69. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Stuck A.E., Staehelin H.B., Orav E.J., et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: A meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169:551-561.
70. Pfeifer M., Begerow B., Minne H.W. VitaminD and muscle function. Osteoporos Int 2002, 13:187-194.
71. Visser M., Deeg D.J.H., Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The longitudinal aging study Amsterdam. J Clin Endocrinol Metab 2003, 88:5766-5772.
72. 3 on fracture healing. An ultrastructural study in healthy guinea pigs. Arch Orthop Trauma Surg 1997, 116:37-40.
73. Heidari B., Heidari P., Hajian-Tilaki K. Association between serum vitamin D deficiency and knee osteoarthritis. Int Orthop 2011, 35:1627-1631.
74. Nawabi D.H., Chin K.F., Keen R.W., Haddad F.S. Vitamin D deficiency in patients with osteoarthritis undergoing total hip replacement: A cause for concern. J Bone Joint Surg Br 2010, 92:496-499.
75. Reid I.R., Bolland M.J., Grey A. Effects of vitamin D supplements on bone mineral density: A systematic review and meta-analysis. Lancet 2014, 383:146-155.
76. Díez Pérez A. Suplementos de vitamina D. Las dosis recomendadas son insuficientes. Med Clin (Barc) 2012, 138:202-203.
77. Caeiro-Rey J.R., Vaquero-Cervino E., Rentero M.L., Calvo-Crespo E., Oteo-Alvaro A., Casillas M. Raloxifene: Mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J. 2009, 3:14-21.
78. Cranney A., Guyatt G. Evidence-Based Rheumatology. Menopausial Osteoporosis 2004, British Medical Journal Books.
79. Silverman S.L., Christiansen C., Genant H.K., Vukicevic S., Zanchetta J.R., Villiers T.J., et al. Efficacy of Bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-yr, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008, 23:1923-1933.
80. Nota informativa de la AEMPS MUH (FV), 9/2013 [consultado Jul 2014]. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2013/docs/NI-MUH_FV_09-2013-calcitonina.htm.
81. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
82. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with risedronate therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
83. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
84. Chesnut C.H., Skag A., Christiansen C. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
85. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of posmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
86. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009, 361:756-765. FREEDOM Trial.
87. Boonen S., Adachi J.D., Man Z., Cummings S.R., Lippuner K., Törring O., et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011, 96:1727-1736.
88. Orwoll E., Teglbjaerg C.S., Langdahl B.L., Chapurlat R., Czerwinski E., Kendler D.L., et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012, 97:3161-3169.
89. Watts N.B., Roux C., Modlin J.F., Brown J.P., Daniels A., Jackson S., et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?. Osteoporos Int. 2012, 23:327-337.
90. Nota informativa de la AEMPS MUH (FV), 13/2014 [consultado 10 Jun 2014]. Disponible en http://aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2014/docs/NI-MUH_FV_13-2014-Denosumab.htm.
91. Khan A.A., Morrison A., Hanley D.A., Felsenberg D., McCauley L.K., O'Ryan F., et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res. 2015, 30:3-23.
92. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio L.H., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
93. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008, 93:2149-2157.
94. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
95. Gosch M., Kammerlander C., Roth T., Doshi H.K., Gasser R.W., Blauth M. Surgeons save bones: An algorithm for orthopedic surgeons managing secondary fracture prevention. Arch Orthop Trauma Surg 2013, 133:101-108.
96. Aspenberg P., Genant H.K., Johanson T., Nino A.J., See K., Krohn K., et al. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, duoble-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010, 25:404-414.
97. Zhang D., Potty A., Vyas P., Lane J. The role of recombinant PTH in human fracture healing: A systematic review. J Orthop Trauma 2014, 28:57-62.
98. Shane E., Ebelling P.R., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2014, 29:1-23.
99. Michalska D., Luchavova M., Zikan V., Raska I., Kubena A.A., Stepan J.J. Effects of morning vs evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Osteoporos Int 2012, 23:2885-2891.
100. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004, 350:459-468.
101. Brennan T.C., Rybchyn M.S., Green W., Atwa S., Conigrave A.D., Mason R.S. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 2009, 157:1291-1300.
102. Reginster J.Y., Seeman E., de Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005, 90:2816-2822.
103. Ranélate de strontium (Protelos): effets indésirables rapportés en France. Presse Med 2011, 40:e453-e462.
104. Nota informativa de la AEMPS MUH (FV), 2/2014 [consultado 10 Jun 2014]. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2014/NI-MUH_FV_02-2014-ranelato-estroncio.htm.
105. Bone H.G., McClung M.R., Roux C., Recker R.R., Eisman J.A., Verbruggen N., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25:937-947.
106. Eisman J.A., Bone H.G., Hosking D.J., McClung M.R., Reid I.R., Rizzoli R., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2011, 26:242-251.
107. Bonnick S., de Villiers T., Odio A., Palacios S., Chapurlat R., DaSilva C., et al. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: A randomized placebo-controlled trial. J Clin Endocrinol Metab 2013, 98:4727-4735.
108. Cusick T., Samadfam R., Duong L. Effects of odanacatib on early and late stage fracture healing in an adult rabbit radial osteotomy model. J Bone Miner Res 2013, 28(Suppl 1).
109. Costa A.G., Bilezikian J.P. Sclerostin: Therapeutic horizons based upon its actions. Curr Osteoporos Rep. 2012, 10:64-72.
110. McColm J., Hu L., Womack T., Tang C.C., Chiang A.Y. Single-and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014, 29:935-943.
111. McClung M.R., Grauer A., Boonen S., Bolognese M.A., Brown J.P., Diez-Perez A., et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014, 370:412-420.
112. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
113. Black D.M., Grenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
114. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
115. Tsai J.N., Uihlein A.V., Lee H., Kumbhani R., Siwila-Sackman E., McKay E.A., et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial. Lancet 2013, 382:50-56.
116. McClung M., Harris S.T., Miller P.D., Bauer D.C., Davison K.S., Dian L., et al. Biphosphonate therapy for osteoporosis: Benefits, risks, and drug holiday. Am J Med 2013, 126:13-20.
117. Reginster J.Y., Bruyere O., Sawicki A., Roces-Varela A., Fardellone P., Roberts A., et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years. Bone 2009, 45:1059-1064.
118. McClung M.R., Lewiecki E.M., Geller M.L., Bolognese M.A., Peacock M., Weinstein R.L., et al. Effect of denosumab on bone mineral density and biomechanical markers of bone turnover: 8 year results of a phase 2 clinical trial. Osteoporos Int 2013, 24:227-235.
119. ® para identificar personas con alto o bajo riesgo de fractura osteoporótica en población femenina española. Med Clin (Barc) 2015, 144:1-8.
120. Cranney A., Guyatt G. Evidence-Based Rheumatology. Menopausal Osteoporosis 2004, British Medical Journal Books.
121. Pham A.N., Datta S.K., Weber T.J., Walter L.C., Colón-Emeric C.S. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectanty. J Am Geriatr Soc 2011, 59:1642-1649.
122. Hiligsmann M., Reginster J.Y. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of postmenospausal osteoporotic women in Belgium. Pharmacoeconomics 2011, 29:895-911.
123. Borgström F., Ström O., Marin F., Kutahov A., Ljunggren O. Cost effectiveness of teriparatide and PTH (1,84) in the treatment of postmenopausal osteoporosis. J Med Econ 2010, 13:381-392.
124. Caeiro-Rey J.R., Etxebarria-Foronda I., Mesa-Ramos M. Fracturas atípicas relacionadas con el uso rolongado de bifosfonatos. Estado de la situación. Rev Esp Cir Ortop Traumatol 2011, 55:392-404.
125. Díaz González J.M., Groba Marco M., Sosa Henríquez M. Coste anual de los fármacos utilizados en el tratamiento de la osteoporosis tras la revisión de los precios de referencia. Rev Osteoporos Metab Miner 2012, 4:43-44.
126. Eriksen E.F., Díez-Pérez A., Boonen S. Update on long-term treatment with bisphosphonates for menopausal osteoporosis: A systematic review. Bone 2014, 58:126-135.
127. Díez-Pérez A., Adachi J.D., Agnusdei D., Bilezikian J.P., Compston J.E., Cummings S.R., et al. Treatment failure in osteoporosis. Osteoporos Int 2012, 23:2769-2774.
128. Díez-Pérez A., Olmos J.M., Nogués X., Sosa M., Díaz-Curiel M., Pérez-Castrillón J.L., et al. Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 2012, 27:817-824.
129. Olmos J.M., Martínez J., González-Macías J. Cómo valorar la respuesta al tratamiento de la osteoporosis. Rev Clin Esp 2008, 208:247-250.
130. Peris P., Guañabens N. Male osteoporosis. Curr Opin Rheumatol 1996, 8:357-364.
131. Kaufman J.M., Reginster J.Y., Boonen S., Brandi M.L., Cooper C., Dere W., et al. Treatment of osteoporosis in men. Bone 2013, 53:134-144.
132. Herrera A., Lobo-Escolar A., Mateo J., Gil J., Ibarz E., Gracia L. Male osteoporosis: A review. World J Orthop 2012, 18:223-234.
133. Venuturupalli S.R., Sacks W. Review of new guidelines for the management of glucocorticoid induced osteoporosis. Curr Osteoporos Rep 2013, 11:357-364.
134. Balasubramanian A., Tosi L.L., Lane J.M., Dirschi D.R., Ho P.R., O'Malley C.D. Decliningrates of osteoporosis management following fragility fractures in the US 2000 through 2009. J Bone Joint Surg Am 2014, 96:e52.
135. Solomon D.H., Johnston S.S., Boytsov N.N., McMorrow D., Lane J.M., Krohn K.D. Osteoporosis medication use after hip fracture in US patients between 2002 and 2011. J Bone Miner Res 2014, 29:1929-1937.
136. Antonelli M., Einstadter D., Magrey M. Screening and treatment of osteoporosis after hip fracture: Comparison of sex and race. J Clin Densitom 2014, 17:479-483.
137. Wilk A., Sajjan S., Modi A., Fan C.P., Mavros P. Post-fracture pharmacotherapy for women with osteoporotic fracture: Analysis of a managed care population in the USA. Osteoporos Int 2014, 25:2777-2786.
138. Sanfélix-Genovés J., Català-López F., Sanfélix-Gimeno G., Hurtado I., Baixauli C., Peiró S. Variabilidad en las recomendaciones para el abordaje clínico de la osteoporosis. Med Clin (Barc) 2014, 142:15-22.
139. Bliuc D., Alarkawi D., Nguyen T.V., Eisman J.A., Center J.R. Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: The Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2015, 30:637-646.
140. Bor A., Matuz M., Gyimesi N., Biczók Z., Soós G., Doró P. Gender inequalities in the treatment of osteoporosis. Mauritas 2015, 80:162-169.
141. Eriksen E.F., Keaveny T.M., Gallager E.R., Krege J.H. Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 2014, 67:246-256.